Mumbai: Union Health Secretary Rajesh Bhushan said on Tuesday that there are six COVID-19 vaccine candidates in clinical trial stages developed by various manufacturers in India.
In addition, three COVID-19 vaccine candidates are in the pre-clinical stage, with one coronavirus vaccine candidate being researched by Aurobindo Pharma in the pre-development stage, the official said.
“Six vaccines are in the clinical trial phase. And there are three vaccines in the pre-clinical stage. Some of them may be licensed in the coming weeks, but we cannot pre-determine this time because the license is national. The domain of observer is. Drugs Controller General of India, Bhushan said at a press conference organized by the Ministry of Health here.
He said, “These vaccines are of two to three doses. COVID-19 precautions must be followed, even after vaccination, as advised by scientists.”
The first vaccine is Covishield, which is being manufactured on the Chimpanzee Adenovirus platform and by the Serum Institute of India (SII) in Pune. The associate company is AstraZeneca. “The regulator had granted Phase 2 and 3 permission for the clinical trial of the vaccine and they have applied for the Emergency Use Authority,” he said.
On Covaxin, he stated that the vaccine is on an inactive virus platform. “It is being produced by Bharat Biotech International Limited, Hyderabad in collaboration with the Indian Council of Medical Research (ICMR). The vaccine is in phase 3 trials. They have also applied for emergency use authorization.”
The third vaccine candidate is ZyCoV-D based on the DNA platform. It is being manufactured by Cadila Healthcare Limited, Ahmedabad. His colleagues are the Department of Biotechnology. It is in Phase 3 of the trial.
The Health Secretary further stated that the fourth vaccine candidate is the Russian vaccine (Sputnik V) based on the human adenoviral platform. It was constructed in Hyderabad by Dr. Is being carried out by Reddy’s laboratory. His colleague is Gamalaya National Center, Russia. Their Phase 3 trial will begin next week.
The fifth vaccine candidate is NVX-CoV2373 which is based on the protein sub-unit platform. It is being developed by the Serum Institute of India, Pune. Their collaborator is Novavax and the phase 3 trial of this vaccine is under consideration in India.
The sixth vaccine candidate is a recombinant protein antigen-based vaccine. It is being manufactured by Biological E Limited, Hyderabad. His colleagues are Massachusetts Institute of Technology, USA. He said pre-clinical animal studies have been looked into for this vaccine.
The seventh vaccine candidate is HGCO 19 which is an mRNA-based vaccine. It is being constructed by Genoa, Pune. His partners are HDT, USA. Pre-clinical animal studies for this vaccine are over. Phase 1 and 2 clinical trials for this vaccine will begin in the near future.
The Health Secretary stated that the eighth vaccine candidate is on the inactive rabies vector platform. “It is being manufactured by Bharat Biotech International Ltd., Hyderabad. Their partners are Thomas Jefferson University, USA. It is in the advanced pre-clinical trial phase.”
“The country’s vaccination efforts are guided by the principles being followed by Prime Minister Narendra Modi from the ramparts of the Red Fort on August 15,” he said.
(With ANI Inputs)